Literature DB >> 16497299

Mechanisms and strategies to overcome multiple drug resistance in cancer.

Tomris Ozben1.   

Abstract

One of the major problems in chemotherapy is multidrug resistance (MDR) against anticancer drugs. ATP-binding cassette (ABC) transporters are a family of proteins that mediate MDR via ATP-dependent drug efflux pumps. Many MDR inhibitors have been identified, but none of them have been proven clinically useful without side effects. Efforts continue to discover not toxic MDR inhibitors which lack pharmacokinetic interactions with anticancer drugs. Novel approaches have also been designed to inhibit or circumvent MDR. In this review, the structure and function of ABC transporters and development of MDR inhibitors are described briefly including various approaches to suppress MDR mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497299     DOI: 10.1016/j.febslet.2006.02.020

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  105 in total

1.  Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.

Authors:  Yan-Jun Mi; Yong-Ju Liang; Hong-Bing Huang; Hong-Yun Zhao; Chung-Pu Wu; Fang Wang; Li-Yang Tao; Chuan-Zhao Zhang; Chun-Ling Dai; Amit K Tiwari; Xiao-Xu Ma; Kenneth Kin Wah To; Suresh V Ambudkar; Zhe-Sheng Chen; Li-Wu Fu
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

2.  A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines.

Authors:  Jessica Castro; Marc Ribó; Teresa Puig; Ramon Colomer; Maria Vilanova; Antoni Benito
Journal:  Invest New Drugs       Date:  2011-02-01       Impact factor: 3.850

3.  Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: the role of glutathione.

Authors:  Heather M Brechbuhl; Remy Kachadourian; Elysia Min; Daniel Chan; Brian J Day
Journal:  Toxicol Appl Pharmacol       Date:  2011-08-10       Impact factor: 4.219

4.  Antitumor Agents 291 Expanded B-Ring Modification Study of 6,8,8-Triethyl Desmosdumotin B Analogues as Multidrug-Resistance Selective Agents.

Authors:  Kyoko Nakagawa-Goto; Kenneth F Bastow; Emika Ohkoshi; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Chem (Los Angeles)       Date:  2011-12-01

Review 5.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Tumor microenvironment and nanotherapeutics.

Authors:  Meenakshi Upreti; Amar Jyoti; Pallavi Sethi
Journal:  Transl Cancer Res       Date:  2013-08-01       Impact factor: 1.241

7.  Special AT-rich sequence binding protein 1 regulates the multidrug resistance and invasion of human gastric cancer cells.

Authors:  Fuqiang Sun; Xiaoming Lu; Hang Li; Zhao Peng; Ke Wu; Guobin Wang; Qiang Tong
Journal:  Oncol Lett       Date:  2012-04-17       Impact factor: 2.967

8.  Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.

Authors:  Laurence Bousquet; Alain Pruvost; Anne-Cécile Guyot; Robert Farinotti; Aloïse Mabondzo
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

9.  Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia.

Authors:  Caihua Gao; Jianying Zhang; Qingyan Wang; Chunhua Ren
Journal:  Oncol Lett       Date:  2016-06-16       Impact factor: 2.967

10.  The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.

Authors:  Suna Zhou; Wenguang Ye; Xiaoyi Duan; Mingxin Zhang; Jiansheng Wang
Journal:  Dig Dis Sci       Date:  2013-01-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.